Explore the latest advances in topoisomerase I inhibitors for cancer treatment, including novel compounds like DIA-001 and their mechanisms of action.
Discover how new indenoisoquinoline compounds target specific cancer vulnerabilities through SLFN11 and BRCA deficiency biomarkers.